Literature DB >> 30534988

DICAM Attenuates Experimental Colitis via Stabilizing Junctional Complex in Mucosal Barrier.

Seung-Woo Han1, Jeong Min Kim2, Yunmee Lho3, Hyun Jung Cho4, Youn-Kwan Jung4, Jung-Ae Kim5, Hoyul Lee6, Yu-Jeong Lee6, Eun Soo Kim6.   

Abstract

BACKGROUND: Adhesion molecules maintain the intestinal barrier function that is crucial to prevent intestinal inflammation. Dual immunoglobulin domain-containing adhesion molecule (DICAM) has been recently identified and known for the involvement in cell-cell adhesion through homophilic interaction and heterophilic interaction with integrin αVβ3. We tested whether the change of DICAM expression affects the severity of colonic inflammation.
METHODS: Colitis was induced with oral administration of 2.5% dextran sulfate sodium (DSS) in 8-week-old male mice for 5 days. The function of DICAM under inflammatory condition was investigated using loss-of-function and gain-of-function models such as DICAM-deficient mice and adenoviral transduction of DICAM into Caco-2 colonic epithelial cells.
RESULTS: DICAM increased in parallel with the degree of inflammation after 5-day administration of DSS and decreased with the resolution of inflammation. DICAM was expressed in the epithelial junctional complex and colocalized with ZO-1. Treatment with TNF-α or IFN-γ in Caco-2 cells significantly increased DICAM in protein and RNA level. The DICAM knockout mice showed more severe DSS-induced colitis compared with WT littermates. Adenoviral transduction of DICAM into Caco-2 cells significantly attenuated the inflammation-mediated decrease of adhesion molecules, including ZO-1 and occludin. Furthermore, Caco-2 cells with DICAM overexpression maintained intestinal barrier function under IFN-γ treatment as estimated by transepithelial electrical resistance.
CONCLUSION: Our study demonstrates that DICAM which is increased in an inflammatory condition has a protective role in experimental colitis by stabilizing the integrity of junctional complex in the intestinal mucosal barrier.
© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  DICAM; adhesion molecule; colitis; mucosal barrier

Mesh:

Substances:

Year:  2019        PMID: 30534988     DOI: 10.1093/ibd/izy373

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  5 in total

1.  An Evolutionary Insertion in the Mxra8 Receptor-Binding Site Confers Resistance to Alphavirus Infection and Pathogenesis.

Authors:  Arthur S Kim; Ofer Zimmerman; Julie M Fox; Christopher A Nelson; Katherine Basore; Rong Zhang; Lorellin Durnell; Chandni Desai; Christopher Bullock; Sharon L Deem; Jonas Oppenheimer; Beth Shapiro; Ting Wang; Sara Cherry; Carolyn B Coyne; Scott A Handley; Michael J Landis; Daved H Fremont; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2020-02-18       Impact factor: 21.023

2.  Antioxidant Analogue 6-Amino-2,4,5-Trimethylpyridin-3-ol Ameliorates Experimental Colitis in Mice.

Authors:  Hoyul Lee; Joon Seop Lee; Hyun Jung Cho; Yu-Jeong Lee; Eun Soo Kim; Sung Kook Kim; Tae-Gyu Nam; Byeong-Seon Jeong; Jung-Ae Kim
Journal:  Dig Dis Sci       Date:  2020-05-02       Impact factor: 3.199

3.  Expression of the Mxra8 Receptor Promotes Alphavirus Infection and Pathogenesis in Mice and Drosophila.

Authors:  Rong Zhang; James T Earnest; Arthur S Kim; Emma S Winkler; Pritesh Desai; Lucas J Adams; Gaowei Hu; Christopher Bullock; Beth Gold; Sara Cherry; Michael S Diamond
Journal:  Cell Rep       Date:  2019-09-03       Impact factor: 9.423

4.  DICAM in the Extracellular Vesicles from Astrocytes Attenuates Microglia Activation and Neuroinflammation.

Authors:  Jin Han; Hyun-Jung Cho; Donghwi Park; Seungwoo Han
Journal:  Cells       Date:  2022-09-24       Impact factor: 7.666

5.  Protective Role of Limitrin in Experimental Autoimmune Optic Neuritis.

Authors:  Bo Young Chun; Jong-Heon Kim; Youn-Kwan Jung; Yoon Seok Choi; Gunwoo Kim; Tomoko Yonezawa; Kyoungho Suk
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-07-01       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.